MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Study Data Expected in Q3 2012
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the
successful completion of patient enrollment in its phase 1b/2a clinical trial
evaluating MOR103, a HuCAL antibody targeting GM-CSF (granulocyte macrophage-
colony stimulating factor). 96 patients with active rheumatoid arthritis (RA)
have been randomized in the double-blind, placebo-controlled study at various
clinical centers in Europe to evaluate the safety and preliminary signs of
clinical activity of MOR103 when administered intravenously in multiple doses.
Data from the trial will become available in Q3 2012.
"Within the past months, MorphoSys's entire proprietary portfolio has advanced
significantly," commented Dr. Arndt Schottelius, Chief Development Officer of
MorphoSys AG. "We currently have four proprietary programs in clinical trials,
all of them targeting novel or better treatment options for severe diseases. We
are well on track to expect a whole range of exciting news from our own
development portfolio in the years to come. GM-CSF is strongly implicated in the
pathogenesis of inflammatory diseases, including rheumatoid arthritis. Data
generated with an antibody targeting the GM-CSF receptor last year provided
further clinical validation of the GM-CSF pathway in RA."
In addition to the RA study, MOR103 is currently being evaluated in two
additional clinical trials. Patient enrollment in a phase 1b dose-escalation
study in multiple sclerosis began in early 2012. A phase 1 pharmacokinetic study
in healthy volunteers to evaluate a subcutaneous formulation of MOR103 will
recruit the final cohort shortly. Subcutaneous injection represents a more
convenient route of administration for patients and the data will help guide
dosing regimens for future clinical trials for MOR103.
In total, MorphoSys currently has four proprietary clinical programs ongoing,
including MOR103 in RA and MS, as well as MOR202, a HuCAL antibody targeting
CD38, in multiple myeloma and MOR208, an Fc-enhanced humanized antibody
targeting CD19, in chronic lymphocytic leukemia and other B-cell malignancies.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company'sAbD Serotec unit uses HuCAL and other antibody technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipeline of more than 70 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just
a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of tomorrow.
MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For
regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), Ylanthia(®), CysDisplay(®),
RapMAT(®) and arYla(®) are registered trademarks of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1591474/500206.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1591474]
Unternehmensinformation / Kurzprofil:
Datum: 06.03.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 121876
Anzahl Zeichen: 5662
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
